Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) General Information
Description
An injection drug for women's healthcare and pain relief. The Duraclon (clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management while Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction.
Contact Information
Corporate Office
- One Riverfront Place
- Newport, KY 41071
- United States
Corporate Office
- One Riverfront Place
- Newport, KY 41071
- United States
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) FAQs
-
Where is Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) headquartered?
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) is headquartered in Newport, KY.
-
What industry is Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) in?
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line)’s primary industry is Buildings and Property.
-
Is Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) a private or public company?
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) is a Private company.
-
What is Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line)’s current revenue?
The current revenue for Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) is .
-
Who are Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line)’s investors?
Xanodyne Pharmaceuticals has invested in Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line).
-
When was Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) acquired?
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) was acquired on 12-Nov-2009.
-
Who acquired Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line)?
Xanodyne Pharmaceuticals (Duraclon and Methadone Hydrochloride Injection USP Product Line) was acquired by Bioniche Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process